NasdaqGM - Nasdaq Real Time Price USD

I-Mab (IMAB)

1.8100

0.0000

(0.00%)

As of 2:23 PM EDT. Market Open.

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on April 11, 2024.

PR Newswire 21 days ago
I-Mab Announces Closing of the Divestiture of Business Operations in China

I-Mab (the "Company") (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that all conditions precedent to the divestiture transaction previously announced on February 7, 2024 (the "Transaction") have been either satisfied or waived and accordingly, the Transaction has successfully closed.

PR Newswire 23 days ago
I-Mab Reports Full Year 2023 Financial Results and Business Update

I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced financial results for the full year ended December 31, 2023, and highlighted recent business updates.

PR Newswire last month
I-Mab Signs Agreement to Divest its Assets and Business Operations in China

I-Mab (the "Company") (NASDAQ: IMAB), a global biotech company exclusively focused on bringing highly differentiated immunotherapies and biologics for cancer treatment to patients around the world, today announced that as part of its strategy to become a U.S.-based biotech, its Chinese subsidiaries have entered into definitive agreements with I-Mab Biopharma (Hangzhou) Co., Ltd. (the "Hangzhou Company"), an unconsolidated affiliate of the Company, and a group of China-based investors to divest t

PR Newswire 2 months ago
I-Mab Announces Participation at Jefferies and Piper Conferences in November

I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced its in-person participation in two conferences in November 2023, the Jefferies London Healthcare Conference and the Piper Sandler 35th Annual Healthcare Conference. Details of the conferences and management presentation are as follows:

PR Newswire 5 months ago
Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, and HI-Bio, a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BT

PR Newswire 5 months ago
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023

I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced that two poster presentations featuring preclinical data on givastomig (also known as TJ-CD4B/ABL111) and TJ-L14B/ABL503, the Company's 4-1BB-targeting bispecific antibody assets, will be reported at the 38th Society for Immunotherapy o

PR Newswire 5 months ago
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023

I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced that the updated clinical results from its Phase 1 study of givastomig (also known as TJ-CD4B/ABL111) in advanced solid tumors will be reported in a poster presentation at the upcoming European Society for Medical Oncology (ESMO) Congre

PR Newswire 6 months ago
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503

I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced multiple recent developments in TJ-L14B/ABL503, a differentiated PD-L1 x 4-1BB bispecific antibody developed in collaboration with ABL Bio (Kosdaq: 298380). TJ-L14B/ABL503 is designed to address tumors resistant to PD-(L)1 antibodies th

PR Newswire 6 months ago
I-Mab Announces Upcoming Participation at September Conferences

I-Mab (Nasdaq: IMAB) (the "Company"), is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics for oncology, today announced its participation in the following conferences in September 2023. Details of the conferences and management presentation are as follows:

PR Newswire 7 months ago
I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

I-Mab (Nasdaq: IMAB) (the "Company"), is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics for oncology, today announced its financial results for the six months ended June 30, 2023, and provided key business updates.

PR Newswire 8 months ago
I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023

I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies, today announced that it will report business and corporate updates and financial results for the six months ended June 30, 2023, before the market opens on Thursday, August 17, 2023, and host a conference call to discuss the results and provide corporate updates at 8:00 a.m. EST.

PR Newswire 8 months ago
I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC

I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies, today announced the publication of a manuscript entitled "CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation" in the latest issue of The Journal for Immuno-Therapy of Cancer (JITC).

PR Newswire 9 months ago
I-Mab Announces the Appointment of Raj Kannan as CEO

I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies, today announced the appointment of Mr. Raj Kannan as the Company's new Chief Executive Officer and a member of the board of directors effective June 22, 2023. This appointment serves as a significant step towards further realizing I-Mab's mission of delivering transformative therapies to patients worldwide.

PR Newswire 9 months ago
I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023

I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced encouraging results from the Phase 1b/2 study (ClinialTrial.gov Identifier: NCT04322006) evaluating uliledlimab, the Company's proprietary and highly differentiated CD73 antibody, in combination with toripalimab (TUOYI®), a PD-1 antibody, in patients with treatment-naïve advanced non-small cell lung cancer (NSCLC), and

PR Newswire 10 months ago
I-MAB Filed 2022 Annual Report on Form 20-F

I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has filed its annual report on Form 20-F for the year ended December 31, 2022 with the U.S. Securities and Exchange Commission ("SEC") on May 1, 2023.

PR Newswire 11 months ago

Performance Overview

Return	IMAB	MSCI WORLD
YTD	-4.74%	+5.33%
1-Year	-42.36%	+19.66%
3-Year	-97.16%	0.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

I-Mab (IMAB)

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

I-Mab Announces Closing of the Divestiture of Business Operations in China

I-Mab Reports Full Year 2023 Financial Results and Business Update

I-Mab Signs Agreement to Divest its Assets and Business Operations in China

I-Mab Announces Participation at Jefferies and Piper Conferences in November

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023

I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503

I-Mab Announces Upcoming Participation at September Conferences

I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023

I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC

I-Mab Announces the Appointment of Raj Kannan as CEO

I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023

I-MAB Filed 2022 Annual Report on Form 20-F

Performance Overview